Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the UK / NCT06451770
Recruiting Phase 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770 · tracked via the Priya Life Science UK tracker
Sponsor
Verve Therapeutics, Inc
Phase
Phase 1
Started
2024-10-30
Last updated
2026-10-23

Condition(s) studied

HypercholesterolemiaHypertriglyceridemiaRefractory Hyperlipidemia

Investigational drug(s) / intervention(s)

VERVE-201

VERVE-201: Intravenous (IV) infusion

Study summary

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.

VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol

Primary outcome measure(s)

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) — Up to Day 365

Trial sites (18)

FacilityCityRegionStatus
Clinical Study Center Garden Grove California Recruiting
Clinical Study Center Clearwater Florida Recruiting
Clinical Study Center Miami Lakes Florida Recruiting
Clinical Study Center Port Orange Florida Recruiting
Clinical Study Center New York New York Recruiting
Clinical Study Center Adelaide Australia Recruiting
Clinical Study Center Melbourne Australia Recruiting
Clinical Study Center Chicoutimi Canada Recruiting
Clinical Study Center Montreal Canada Recruiting
Clinical Study Center Toronto Canada Recruiting
Clinical Study Center Amsterdam Netherlands Recruiting
Clinical Study Center Rotterdam Netherlands Recruiting
Clinical Study Center Cape Town South Africa Recruiting
Clinical Study Center Johannesburg South Africa Recruiting
Clinical Study Center Liverpool United Kingdom Recruiting
Clinical Study Center London United Kingdom Recruiting
Clinical Study Center 2 Manchester United Kingdom Recruiting
Clinical Study Center Manchester United Kingdom Recruiting

More Verve Therapeutics, Inc. trials in the UK

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease Recruiting
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease Enrolling by invitation

Other trials for the same condition

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Active, not recruiting
Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia Active, not recruiting
Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease Enrolling by invitation
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06451770 on ClinicalTrials.gov ↗ ← All trials in the UK